News
Boehringer puts IBM's genAI into its antibody discovery tank
In another example of the pharma industry embracing generative artificial intelligence (genAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibod
R&D
Sponsored
Revolutionising research: Inside the NCVR evolution in the U...
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio
Patients
‘What If?’ Poetry as a platform for the patient voice
Patient centricity has been a key focus for pharma in 2023. However, extending beyond the merely discursive topic into sustained and tangible action at scale has been somewhat limited.
Oncology
Sponsored
Patient Centricity to Integration: Enhancing Cancer Outcomes
We are living in an era of unprecedented advances in cancer treatments with transformative therapies being regularly approved.
Sales & Marketing
Sponsored
Before you start the strategic planning cycle: 5 essential t...
It’s about that time of year when many global teams turn their attention towards annual strategic planning.
R&D
Partner Content
3rd mRNA Analytical Development Summit
180+ Technical mRNA Specialists | 35+ Expert Speakers | 2 Content Streams
R&D
Partner Content
6th Chronic Kidney Disease Drug Development Summit
The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to strengthen proteinuria and GFR slope as surrogates for long-term outcomes, and a wave of
Category :
Views & Analysis
/